Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 1
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Efzofitimod for the Treatment of Pulmonary Sarcoidosis.
Culver DA, Aryal S, Barney J, Hsia CCW, James WE, Maier LA, Marts LT, Obi ON, Sporn PHS, Sweiss NJ, Shukla S, Kinnersley N, Walker G, Baughman R. Culver DA, et al. Chest. 2023 Apr;163(4):881-890. doi: 10.1016/j.chest.2022.10.037. Epub 2022 Nov 8. Chest. 2023. PMID: 36356657 Free PMC article. Clinical Trial.
RESEARCH QUESTION: What is the tolerability, safety, and effect on outcomes of efzofitimod in pulmonary sarcoidosis? STUDY DESIGN AND METHODS: In this randomized, double-blind, placebo-controlled study evaluating multiple ascending doses of efzofitimod administered …
RESEARCH QUESTION: What is the tolerability, safety, and effect on outcomes of efzofitimod in pulmonary sarcoidosis? STUDY DESIGN AND …
Efzofitimod: a novel anti-inflammatory agent for sarcoidosis.
Baughman RP, Niranjan V, Walker G, Burkart C, Paz S, Chong Y, Siefker D, Sun E, Nangle L, Forster S, Muders M, Farver C, Lower E, Shukla S, Culver DA. Baughman RP, et al. Sarcoidosis Vasc Diffuse Lung Dis. 2023 Mar 28;40(1):e2023011. doi: 10.36141/svdld.v40i1.14396. Sarcoidosis Vasc Diffuse Lung Dis. 2023. PMID: 36975051 Free PMC article.
A dose escalating trial of efzofitimod in sarcoidosis with chronic symptomatic pulmonary disease found that treatment with efzofitimod was associated with improved quality of life with a trend towards reduced glucocorticoid use and stable to improved pulmonary funct …
A dose escalating trial of efzofitimod in sarcoidosis with chronic symptomatic pulmonary disease found that treatment with efzofit …
Anti-inflammatory Therapy for Sarcoidosis.
Obi ON. Obi ON. Clin Chest Med. 2024 Mar;45(1):131-157. doi: 10.1016/j.ccm.2023.08.010. Epub 2023 Sep 9. Clin Chest Med. 2024. PMID: 38245362 Review.
Exposure-response analyses of efzofitimod in patients with pulmonary sarcoidosis.
Walker G, Adams R, Guy L, Chandrasekaran A, Kinnersley N, Ramesh P, Zhang L, Brown F, Niranjan V. Walker G, et al. Front Pharmacol. 2023 Oct 3;14:1258236. doi: 10.3389/fphar.2023.1258236. eCollection 2023. Front Pharmacol. 2023. PMID: 37854715 Free PMC article.
Background: Preliminary evidence for efficacy in pulmonary sarcoidosis has been shown for efzofitimod. Here we present supportive evidence of efficacy based on an exposure-response analysis. ...Linear regression described the relationship of efzofitimod exposure and …
Background: Preliminary evidence for efficacy in pulmonary sarcoidosis has been shown for efzofitimod. Here we present supportive evi …
Developmental drugs for sarcoidosis.
Obi ON, Saketkoo LA, Maier LA, Baughman RP. Obi ON, et al. J Autoimmun. 2024 Mar 28:103179. doi: 10.1016/j.jaut.2024.103179. Online ahead of print. J Autoimmun. 2024. PMID: 38548579
Development and Characterization of a Novel Neuropilin-2 Antibody for Immunohistochemical Staining of Cancer and Sarcoidosis Tissue Samples.
Förster S, Chong YE, Siefker D, Becker Y, Bao R, Escobedo E, Qing Y, Rauch K, Burman L, Burkart C, Kainz P, Cubitt A, Muders M, Nangle LA. Förster S, et al. Monoclon Antib Immunodiagn Immunother. 2023 Oct;42(5):157-165. doi: 10.1089/mab.2023.0007. Monoclon Antib Immunodiagn Immunother. 2023. PMID: 37902990
Neuropilin-2 (NRP2) is a cell surface receptor that plays key roles in lymphangiogenesis, but also in pathophysiological conditions such as cancer and inflammation. NRP2 targeting by efzofitimod, a novel immunomodulatory molecule, is currently being tested for the treatmen …
Neuropilin-2 (NRP2) is a cell surface receptor that plays key roles in lymphangiogenesis, but also in pathophysiological conditions such as …